Tenax Therapeutics (NASDAQ:TENX) Earns Overweight Rating from Cantor Fitzgerald

Posted by Geri Gentry on Jul 29th, 2026

Tenax Therapeutics (NASDAQ:TENX – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $35.00 price objective on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 121.52% from the company’s previous close.

TENX has been the topic of several other research reports. Evercore began coverage on Tenax Therapeutics in a research report on Wednesday, July 22nd. They set an “outperform” rating and a $39.00 target price on the stock. Piper Sandler raised their price target on Tenax Therapeutics from $20.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, June 12th. Chardan Capital restated a “buy” rating and issued a $27.00 price target on shares of Tenax Therapeutics in a research note on Thursday, July 2nd. Canaccord Genuity Group started coverage on Tenax Therapeutics in a report on Tuesday. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Guggenheim reiterated a “buy” rating and issued a $40.00 price objective (up from $34.00) on shares of Tenax Therapeutics in a research report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Tenax Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Read Our Latest Research Report on TENX

Tenax Therapeutics Stock Down 2.4%

Shares of NASDAQ:TENX opened at $15.80 on Wednesday. Tenax Therapeutics has a fifty-two week low of $5.78 and a fifty-two week high of $19.40. The firm’s 50-day simple moving average is $13.48 and its 200-day simple moving average is $13.56. The company has a market cap of $419.10 million, a price-to-earnings ratio of -11.29 and a beta of 0.92.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. On average, research analysts forecast that Tenax Therapeutics will post -1.48 EPS for the current year.

Institutional Investors Weigh In On Tenax Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC lifted its position in shares of Tenax Therapeutics by 19.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 63,673 shares of the specialty pharmaceutical company’s stock valued at $776,000 after acquiring an additional 10,245 shares during the period. Letko Brosseau & Associates Inc. acquired a new stake in shares of Tenax Therapeutics in the 4th quarter worth approximately $130,000. Virtu Financial LLC purchased a new position in Tenax Therapeutics in the 3rd quarter valued at approximately $92,000. Corient Private Wealth LLC purchased a new position in Tenax Therapeutics in the 4th quarter valued at approximately $151,000. Finally, Bank of America Corp DE raised its holdings in Tenax Therapeutics by 391.2% during the first quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company’s stock worth $297,000 after purchasing an additional 14,789 shares during the last quarter. 1.67% of the stock is currently owned by institutional investors and hedge funds.

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.